Report: Access to Biosimilars May Increase Access to Treatment for Cancer Patients Worldwide
A new biosimilar to trastuzumab (Herceptin) has proven effective in treating women without prior treatment for ERBB2 (HER2)-positive metastatic breast cancer. Trastuzumab is a biologic, a drug comprised of large, complex molecules derived from living organisms. Biosimilars have to demonstrate they are “highly similar” to the reference biologic product, but head-to-head studies are not required for approval. In this case, researchers performed a head-to-head study to compare the proposed trastuzumab biosimilar along with taxane to trastuzumab plus taxane in a 1:1 double-blind, randomized, parallel-group, Phase III equivalency study in 458 treatment-naïve women presenting with ERBB2-positive metastatic breast cancer. The overall response rate at 24 weeks was 69.6% for the biosimilar-based treatment vs. 64.0% for trastuzumab (overall response rate ratio, 1.09; 90% confidence interval, 0.974-1.211). At week 48, there was no statistical difference for time-to-tumor progression, progression-free survival, or overall survival. Adverse events were similar. The authors concluded that use of a proposed trastuzumab biosimilar compared with trastuzumab resulted in an equivalent overall response rate at 24 weeks (JAMA 2017;317:37-47). Two separate editorials lauded the findings of this study and suggested biosimilars may increase access to treatment for cancer patients worldwide.
A new biosimilar to trastuzumab has proven effective in treating women without prior treatment for ERBB2 (HER2)-positive metastatic breast cancer.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.